annual meeting program - American Society of Clinical Oncology

MONDAY
Monday, June 7, 2010
Brd. 19 Randomized phase III study of carboplatin plus S-1 compared with
carboplatin plus paclitaxel as first-line chemotherapy in advanced non-small
cell lung cancer (WJTOG3605). (Abstract #7530)
H. Yoshioka, I. Okamoto, S. Morita, M. Ando, K. Takeda, T. Seto, N. Yamamoto,
S. Nakamura, M. Fukuoka, K. Nakagawa, West Japan Oncology Group (WJOG)
Brd. 20 Phase II trial of ipilimumab (IPI) and paclitaxel/carboplatin (P/C) in first-line
stage IIIb/IV non-small cell lung cancer (NSCLC). (Abstract #7531)
T. J. Lynch, I. N. Bondarenko, A. Luft, P. Serwatowski, F. Barlesi, R. T. Chacko,
M. Sebastian, J. Siegel, J. Cuillerot, M. Reck
Brd. 22 Randomized trial of concurrent versus sequential docetaxel (Doc) plus
bortezomib (PS-341) in platinum pretreated non-small cell lung cancer
(NSCLC). (Abstract #7533)
P. Lara, J. Longmate, A. Argiris, B. J. Gitlitz, P. C. Mack, D. H. Lau, M. Koczywas,
N. B. Leighl, D. R. Gandara
Brd. 23 A randomized phase II study of paclitaxel (P) and carboplatin (C) �
bevacizumab (B) � dulanermin (D) in non-small cell lung cancer (NSCLC).
(Abstract #7534)
F. H. Blackhall, Z. Márk, P. Zatloukal, B. Szima, I. Albert, E. Juhász, X. Yang,
D. Smethurst, Y. Hei, J. Soria
Brd. 24 Phase II study of PRO95780 plus paclitaxel, carboplatin, and bevacizumab
(PCB) in non-small cell lung cancer (NSCLC). (Abstract #7535)
C. S. Karapetis, P. R. Clingan, N. B. Leighl, B. Durbin-Johnson, V. O’Neill,
D. R. Spigel
340